Stella Pharma Corp. (4888) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Stella Pharma Corp. (4888:JPX), powered by AI.

Current Price
¥334
P/E Ratio
-79.2
Market Cap
11.1B
Sector
Healthcare
What is the Stella Pharma Corp. stock price forecast?

Stella Pharma Corp. is currently trading at ¥334. View real-time AI analysis on Alpha Lenz.

What is Stella Pharma Corp. insider trading activity?

View the latest insider trading data for Stella Pharma Corp. on Alpha Lenz.

What is Stella Pharma Corp.'s P/E ratio?

Stella Pharma Corp.'s P/E ratio is -79.2.

Stella Pharma Corp.

JPX · 4888
¥334+1(+0.30%)Market closedJPX regular session 09:00–15:00 JST
Ask about Stella Pharma Corp.'s future dividend policy...
Alpha Chat Insight

Stella Pharma Corp. trades at a P/E of -79.2 (undervalued) with modest ROE of -5.0%. 3Y revenue CAGR of 112.5% highlights clear growth momentum.

Ask for details

Company Overview

Stella Pharma Corp. is a prominent player in the pharmaceutical industry, focusing on the development, production, and distribution of medical products and therapies. The company's primary mission is to address unmet medical needs through innovative and effective solutions, targeting a wide range of health conditions. Stella Pharma's product portfolio spans across various therapeutic areas, including oncology, cardiology, immunology, and infectious diseases, showcasing its dedication to improving patient outcomes globally. With a robust research and development pipeline, Stella Pharma invests heavily in cutting-edge technologies and partnerships, enhancing its capability to bring novel treatments to market. The company operates globally, collaborating with medical institutions, research organizations, and healthcare providers to ensure comprehensive healthcare solutions. Its market significance is underscored by its commitment to maintaining high standards of quality, safety, and efficacy in all its products, reinforcing trust and reliability among healthcare professionals and patients alike. As the healthcare landscape evolves, Stella Pharma continues to play a vital role in shaping the future of medicine through its relentless pursuit of innovation and excellence.

CEOMr. Tomoyuki Asano
SectorHealthcare
IndustryBiotechnology
Employees43

Company Statistics

FY 2025

Profile

¥11,148,819,132Market Cap
¥961,058,000Revenue
0.00Shares Out
43Employees

Margins

88.00%Gross
-10.31%EBITDA
-9.39%Operating
-14.35%Pre-Tax
-14.65%Net

Valuation

-79.18P/E
3.48P/B
11.60EV/Sales
-87.91EV/EBITDA
87.10P/FCF

Growth (CAGR)

112.54%Rev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-3.05%ROA
-5.04%ROE
-2.90%ROIC

Financial Health

¥3,206,471,000Cash & Cash Equivalents
¥-996,853,000Net Debt
68.89%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Stella Pharma Corp. (ticker: 4888) is a company listed on JPX in the Healthcare sector (Biotechnology). It has approximately 43 employees. Market cap is $11.1B.

The current price is 334 with a P/E ratio of -79.18x and P/B of 3.48x.

ROE is -5.04% and operating margin is -9.39%. Annual revenue is $961M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Stella Pharma Corp. (4888) Stock Forecast 2026 ¥334 — Price, Financials & Analyst Targets | Alpha Lenz